Le point sur l’asthme en pédiatrie : optimisation de la prise en charge et thérapies biologiques [Where we stand with asthma: optimized medical care and biologic therapy for children]
Details
Request a copy Under embargo until 22/08/2024.UNIL restricted access
State: Public
Version: Final published version
License: CC BY-NC-ND 4.0
Serval ID
serval:BIB_469DBB5891AC
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Le point sur l’asthme en pédiatrie : optimisation de la prise en charge et thérapies biologiques [Where we stand with asthma: optimized medical care and biologic therapy for children]
Journal
Revue medicale suisse
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
22/02/2023
Peer-reviewed
Oui
Volume
19
Number
815
Pages
354-357
Language
french
Notes
Publication types: English Abstract ; Journal Article
Publication Status: ppublish
Publication Status: ppublish
Abstract
Asthma recommendations are in constant evolution. Salbutamol exclusivity as the historical reference treatment for asthma exacerbations is now questioned. In case of light to moderate crisis, budesonide/formoterol, combining an inhaled corticosteroid and a fast acting long lasting beta2 agonist, can now be proposed as first line as needed treatment, for adolescents older than 12 years old. In addition, progress in fundamental research revealed the heterogeneous nature of asthma and allowed for the emergence of new-targeted therapies.
Keywords
Adolescent, Child, Humans, Budesonide/therapeutic use, Formoterol Fumarate/therapeutic use, Anti-Asthmatic Agents/therapeutic use, Ethanolamines/therapeutic use, Asthma/drug therapy, Biological Therapy, Administration, Inhalation, Drug Combinations, Bronchodilator Agents/therapeutic use
Pubmed
Create date
03/03/2023 14:56
Last modification date
31/10/2023 8:15
Usage data
